BioDelivery Sciences Reports Strong Second Quarter 2018 Financial Results

BioDelivery Sciences International (NASDAQ:BDSI), a leading specialty pharmaceutical company focused on patients living with chronic pain, today reported financial results for the second quarter ending June 30, 2018, as well as the following operational and performance highlights.

As quoted in the press release:

“The second quarter was highlighted by strong prescription growth, organization development, and execution across the Company that has resulted in significant progress toward our 2018 goals,” said Herm Cukier, Chief Executive Officer of BDSI.  “Based on the current prescription momentum and further growth potential, we believe the opportunity for BELBUCA longer term may well be more than $200 million per year.  This has been a successful first half of the year, and I am confident in our ability to continue to execute effectively going forward.”

The Company also announced that management has established a growth plan for BELBUCA which is expected to capitalize on the long-term potential of the product.  The plan includes further expansion of the sales team, building out the market access and medical affairs teams, and creating a consumer social media plan.  More information will be provided at an upcoming analyst meeting to be held later this year.

Click here to read the full press release.